Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.